Individuals who may require lower amounts: the elderly, those very sensitive to drugs, and individuals on long term nutrient rich diets
Halbgebauer D, Roos J, Funcke JB, Neubauer H, Hamilton BS, Simon E, Amri EZ, Debatin KM, Wabitsch M, Fischer-Posovszky P, Tews D
PTPN22 (short for protein tyrosine phosphatase non-receptor type 22), known as a risk factor in multiple autoimmune disorders, reduces T-cell activity by removing phosphate groups from phosphorylated proteins such as LCK, Fyn, and Zap70, which are associated with T-cell receptor signaling pathway
The FDA documented over 520 adverse event reports related to compounded semaglutide as of April 2025
The choice of treatment is based on individual lifestyle preferences, clinical goals, and your doctors recommendation